Boston Scientific Co. (NYSE:BSX) Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 17.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,771,935 shares of the medical equipment provider’s stock after purchasing an additional 694,585 shares during the quarter. Fisher Asset Management LLC owned approximately 0.32% of Boston Scientific worth $399,888,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Triad Wealth Partners LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Values First Advisors Inc. purchased a new position in shares of Boston Scientific during the 3rd quarter worth approximately $28,000. Andra AP fonden acquired a new position in shares of Boston Scientific during the 2nd quarter worth approximately $29,000. Lynx Investment Advisory purchased a new stake in Boston Scientific in the 2nd quarter valued at approximately $30,000. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new stake in Boston Scientific during the 3rd quarter valued at $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 162,777 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the transaction, the chief executive officer now directly owns 1,572,096 shares of the company’s stock, valued at approximately $133,046,484.48. This represents a 9.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the sale, the executive vice president now owns 37,468 shares in the company, valued at $3,061,135.60. The trade was a 15.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 314,147 shares of company stock valued at $26,643,598. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 1.6 %

NYSE:BSX opened at $90.00 on Monday. The stock has a 50-day simple moving average of $85.99 and a 200 day simple moving average of $80.22. Boston Scientific Co. has a one year low of $53.93 and a one year high of $91.93. The company has a market capitalization of $132.64 billion, a price-to-earnings ratio of 74.38, a price-to-earnings-growth ratio of 2.69 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the previous year, the business earned $0.50 EPS. The business’s quarterly revenue was up 19.3% on a year-over-year basis. Sell-side analysts predict that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of recent research reports. Mizuho lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Stifel Nicolaus upped their price objective on shares of Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Truist Financial boosted their price target on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James raised their price objective on Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a report on Wednesday, September 4th. Finally, Canaccord Genuity Group increased their target price on Boston Scientific from $88.00 to $98.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Four research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.